Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 46 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Pipeline Review, H1 2016', provides in depth analysis on Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) targeted pipeline therapeutics. 

The report provides comprehensive information on the Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12)
- The report reviews Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) Overview 7
Therapeutics Development 8
Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Products under Development by Stage of Development 8
Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Products under Development by Therapy Area 9
Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Products under Development by Indication 10
Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Pipeline Products Glance 11
Early Stage Products 11
Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Products under Development by Companies 12
Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Products under Development by Universities/Institutes 14
Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 18
Assessment by Molecule Type 19
Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Companies Involved in Therapeutics Development 21
Angelini Group 21
Aurigene Discovery Technologies Limited 22
Calico LLC 23
FORMA Therapeutics, Inc. 24
Genentech, Inc. 25
Karyopharm Therapeutics, Inc. 26
OncoTartis, Inc. 27
Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Drug Profiles 28
AU-4869 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Drug to Inhibit NAMPT for Inflammation and Pain - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
GNE-617 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
KPT-9274 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
OT-82 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
P- BEFizumab - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
P7-C3A20 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Small Molecules to Activate NAMPT for Neurological Disorders - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Small Molecules to Inhibit NAMPT for Cancer - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Small Molecules to Inhibit NAMPT for Oncology - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
STF-118804 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Dormant Projects 40
Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Discontinued Products 41
Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Featured News & Press Releases 42
Mar 16, 2016: Karyopharm to Present Data on Oncology drug KPT-9274 at the 2016 American Association for Cancer Research Annual Meeting 42
Apr 18, 2015: Aurigene to Present its NAMPT Inhibitors Programs at AACR 2015 43
Nov 01, 2013: Novel drug discovery method designed by Stanford scientists 43
Apr 02, 2013: Aurigene To Present Poster On NAMPT Inhibitor Program At AACR 2013 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 45
Disclaimer 46

List of Tables

Number of Products under Development for, H1 2016 8
Number of Products under Development by Therapy Area, H1 2016 9
Number of Products under Development by Indication, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Assessment by Monotherapy/Combination Products, H1 2016 16
Number of Products by Stage and Mechanism of Action, H1 2016 17
Number of Products by Stage and Route of Administration, H1 2016 18
Number of Products by Stage and Molecule Type, H1 2016 20
Pipeline by Angelini Group, H1 2016 21
Pipeline by Aurigene Discovery Technologies Limited, H1 2016 22
Pipeline by Calico LLC, H1 2016 23
Pipeline by FORMA Therapeutics, Inc., H1 2016 24
Pipeline by Genentech, Inc., H1 2016 25
Pipeline by Karyopharm Therapeutics, Inc., H1 2016 26
Pipeline by OncoTartis, Inc., H1 2016 27
Dormant Projects, H1 2016 40
Discontinued Products, H1 2016 41